LimmaTech Biologics

LimmaTech Biologics is a clinical-stage Swiss biotechnology company specializing in the development of next-generation vaccines to combat antimicrobial resistance and life-threatening bacterial infections. Spun out of GlycoVaxyn following its acquisition by GSK in 2015, the company leverages a proprietary enzymatic bioconjugation platform to create complex multivalent glycoconjugate vaccines. Its lead program is a vaccine candidate for Shigella, currently in Phase 2 clinical trials, which is being developed in collaboration with partners like Valneva. LimmaTech's pipeline also includes programs targeting Klebsiella pneumoniae and Staphylococcus aureus, aiming to address significant unmet medical needs in global health.